Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Randon G, Kook MC, An JY, Grabsch HI, Prisciandaro M, Nichetti F, Noh SH, Sohn TS, Kim S, Wotherspoon A, Morano F, Cunningham D, Lee J, Cheong JH, Smyth EC, Pietrantonio F. Raimondi A, et al. Among authors: morano f. Eur J Cancer. 2024 May;203:114043. doi: 10.1016/j.ejca.2024.114043. Epub 2024 Apr 4. Eur J Cancer. 2024. PMID: 38598921
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
Pietrantonio F, Oddo D, Gloghini A, Valtorta E, Berenato R, Barault L, Caporale M, Busico A, Morano F, Gualeni AV, Alessi A, Siravegna G, Perrone F, Di Bartolomeo M, Bardelli A, de Braud F, Di Nicolantonio F. Pietrantonio F, et al. Among authors: morano f. Cancer Discov. 2016 Sep;6(9):963-71. doi: 10.1158/2159-8290.CD-16-0297. Epub 2016 Jun 20. Cancer Discov. 2016. PMID: 27325282
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M. Pietrantonio F, et al. Among authors: morano f. Int J Cancer. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408. Epub 2016 Sep 16. Int J Cancer. 2016. PMID: 27578417 Free article.
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases.
Pietrantonio F, Di Bartolomeo M, Cotsoglou C, Mennitto A, Berenato R, Morano F, Coppa J, Perrone F, Iacovelli R, Milione M, Alessi A, Vaiani M, Bossi I, Ricchini F, Scotti M, Caporale M, Bajetta E, de Braud F, Mazzaferro V. Pietrantonio F, et al. Among authors: morano f. Clin Colorectal Cancer. 2017 Sep;16(3):e191-e198. doi: 10.1016/j.clcc.2016.09.007. Epub 2016 Oct 6. Clin Colorectal Cancer. 2017. PMID: 27979717 Clinical Trial.
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Sclafani F, Brown G, Cunningham D, Rao S, Tekkis P, Tait D, Morano F, Baratelli C, Kalaitzaki E, Rasheed S, Watkins D, Starling N, Wotherspoon A, Chau I. Sclafani F, et al. Among authors: morano f. Oncologist. 2017 Jun;22(6):728-736. doi: 10.1634/theoncologist.2016-0396. Epub 2017 May 5. Oncologist. 2017. PMID: 28476941 Free PMC article. Clinical Trial.
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.
Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fucà G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A, Pietrantonio F, Di Nicolantonio F. Oddo D, et al. Among authors: morano f. Br J Cancer. 2017 Jul 25;117(3):347-352. doi: 10.1038/bjc.2017.196. Epub 2017 Jun 27. Br J Cancer. 2017. PMID: 28654634 Free PMC article.
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
Berenato R, Morano F, Pietrantonio F, Cotsoglou C, Caporale M, Infante G, Pellegrinelli A, Alessi A, Battiston C, Coppa J, Padovano B, Mennitto A, Niger M, Fucà G, Lazzati S, Greco G, Delconte G, de Braud F, Mazzaferro V, Di Bartolomeo M. Berenato R, et al. Among authors: morano f. Oncology. 2017;93(5):279-286. doi: 10.1159/000479154. Epub 2017 Sep 8. Oncology. 2017. PMID: 28881354 Clinical Trial.
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, Di Bartolomeo M. Pietrantonio F, et al. Among authors: morano f. Clin Cancer Res. 2018 Mar 1;24(5):1082-1089. doi: 10.1158/1078-0432.CCR-17-2781. Epub 2017 Dec 5. Clin Cancer Res. 2018. PMID: 29208673 Free article.
110 results